Professor Dror Harats, CEO of VBL Therapeutics on ILTV News described the Phase 2 results of VB-111. The treatment (now in Phase 3 trials) doubles survival time for brain tumor patients and ovarian cancer patients.  It works for most solid tumor cancers.

(Reported here previously)

https://www.youtube.com/embed/4HeISdYw7d8?rel=0